TABLE 1.
Characteristics of patients with insular glioma according to the classification.
| Characteristic | Total | Classification | p value | ||
|---|---|---|---|---|---|
| 1 | 2 | 3 | |||
| Number of patients | 283 | 140 | 63 | 80 | |
| Age(years) | |||||
| ≥40 | 153 (54.1%) | 64 (45.7%) | 33 (52.4%) | 56 (70.0%) | 0.002 |
| Median | 40 | 38 | 40 | 43 | |
| Sex (Male) | 154 (54.4%) | 79 (56.4%) | 34 (54.0%) | 41 (51.3%) | 0.757 |
| Side (Left) | 143 (50.5%) | 72 (51.4%) | 26 (41.3%) | 45 (56.3%) | 0.197 |
| Preoperative seizure | 156 (55.1%) | 68 (48.6%) | 34 (54.0%) | 43 (53.8%) | 0.674 |
| Tumor volume (cm3) | |||||
| ≥70 | 136 (48.1%) | 36 (25.7%) | 34 (54.0%) | 66 (82.5%) | <0.001 |
| Median | 70.7 | 47.5 | 75.1 | 114.4 | |
| Enhancement | 93 (32.9%) | 26 (18.6%) | 21 (33.3%) | 46 (57.5%) | <0.001 |
| Histological grade 3 | 97 (34.3%) | 27 (19.3%) | 30 (47.6%) | 40 (50.0%) | <0.001 |
| 1p/19q | 232 | ||||
| Codeletion | 90 (38.8%) | 48 (40.7%) | 17 (36.2%) | 25 (37.3%) | 0.829 |
| Intact | 142 (61.2%) | 70 (59.3%) | 30 (63.8%) | 42 (62.7%) | |
| NA | 51 | ||||
| MGMT | 203 | ||||
| Methylation | 142 (70.0%) | 75 (71.4%) | 30 (71.4%) | 37 (66.1%) | 0.699 |
| Unmethylated | 61 (30.0%) | 30 (28.8%) | 12 (27.9%) | 19 (33.9%) | |
| NA | 80 | ||||
| IDH1/2 | 177 | ||||
| Mutation | 138 (78.0%) | 76 (87.4%) | 34 (82.9%) | 28 (57.1%) | <0.001 |
| Wild‐type | 39 (22.0%) | 11 (12.8%) | 7 (16.7%) | 21 (42.9%) | |
| NA | 106 | ||||
| TERT | 152 | ||||
| Mutation | 66 (43.4%) | 35 (43.8%) | 12 (37.5%) | 19 (47.5%) | 0.759 |
| Wild‐type | 86 (56.6%) | 45 (56.3%) | 20 (62.5%) | 21 (52.5%) | |
| NA | 131 | ||||
| Ki‐67 index | 165 | ||||
| ≥10% | 88 (53.3%) | 39 (44.3%) | 19 (54.3%) | 30 (71.4%) | 0.015 |
| <10% | 77 (46.7%) | 49 (55.7%) | 16 (45.7%) | 12 (28.6%) | |
| NA | 118 | ||||
| EOR | |||||
| ≥90% | 199 (70.3%) | 115 (82.1%) | 44 (69.8%) | 40 (50.0%) | <0.001 |
| <90% | 84 (29.7%) | 25 (17.9%) | 19 (30.2%) | 40 (50.0%) | |
| Additional treatment | 259 | ||||
| None | 63 (24.3%) | 40 (28.6%) | 9 (14.3%) | 14 (19.2%) | |
| Chemo | 41 (15.8%) | 17 (13.5%) | 10 (16.7%) | 14 (19.2%) | |
| Radiotherapy | 51 (19.7%) | 26 (20.6%) | 16 (26.7%) | 9 (12.3%) | |
| Radiotherapy and chemo | 104 (40.2%) | 44 (34.9%) | 24 (40.0%) | 36 (49.3%) | |
| NA | 24 | ||||
| Postoperative complication | 243 | ||||
| Motor impairment | 19 (7.8%) | 6 (4.9%) | 4 (7.5%) | 9 (13.2%) | 0.123 |
| Language disorder | 17 (7.0%) | 8 (6.6%) | 4 (7.5%) | 5 (7.4%) | 0.964 |
| NA | 40 | ||||
Note: Boldface type indicates statistical significance.
Abbreviations: Chemo, chemotherapy; EOR, extent of resection; IDH, isocitrate dehydrogenase; MGMT, methylguanine methyltransferase gene; TERT, telomerase reverse transcriptase gene.